Accreditation Expired
NASH: Current and future therapies
GlobalThe landscape of currently available and developmental therapies for NASH, produced in association with Hepatology Knowledge into Practice
NASH: Current and future therapies
NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.
Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must watch the video and successfully pass the post-module assessment.
Pre-Activity Information
Hepatologists, endocrinologists, diabetologists, gastroenterologists, GPs
This educational activity is intended for an international audience of non-US and non-UK HCPs.
After taking part in this activity, learners will be able to discuss current and emerging therapies in the management of NASH
Faculty: Professor Philip Newsome
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Grants/Research Support recipient | Novo Nordisk, Boehringer Ingelheim |
| Consultant on behalf of the University of Birmingham | Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals |
Staff Disclosures
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
This module was accredited on the 6th June 2022 and will expire on the 6th June 2023.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.